Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/151472
Title: Ligand-activated progesterone receptor B activates transcription factor EB to promote autophagy in human breast cancer cells
Authors: Tan, Sijie
Bajalovic, Natasa
Wong, Esther S. P.
Lin, Valerie Chun Ling
Keywords: Science::Biological sciences
Issue Date: 2019
Source: Tan, S., Bajalovic, N., Wong, E. S. P. & Lin, V. C. L. (2019). Ligand-activated progesterone receptor B activates transcription factor EB to promote autophagy in human breast cancer cells. Experimental Cell Research, 382(1), 111433-. https://dx.doi.org/10.1016/j.yexcr.2019.05.014
Project: MOE2014-T2-2-125
Journal: Experimental Cell Research
Abstract: Autophagy is an evolutionary conserved, self-eating process that targets cellular constituents for lysosomal degradation. Transcription factor EB (TFEB) is a master regulator of autophagy by inducing the expression of genes involved in autophagic and lysosomal degradation. In breast cancer, ligand-activated progesterone receptor has been reported to influence cancer development by manipulating the autophagy pathway. However, understanding of the mechanism that underlies this autophagic response remains limited. Herein, we report that prolonged treatment with progestin R5020 upregulates autophagy in MCF-7 human breast cancer cells via a novel interplay between progesterone receptor B (PRB) and TFEB. R5020 upregulates TFEB gene expression and protein levels in a PRB-dependent manner. Additionally, R5020 enhances the co-recruitment of PRB and TFEB to each other to facilitate TFEB nuclear localization. Once in the nucleus, TFEB induces the expression of autophagy and lysosomal genes to potentiate autophagy. Together, our findings highlight a novel functional connection between ligand-activated PRB and TFEB to modulate autophagy in MCF-7 breast cancer cells. As breast cancer development is controlled by autophagy, the progestin-PRB-TFEB transduction pathway warrants future attention as a potential therapeutic target in cancer therapy.
URI: https://hdl.handle.net/10356/151472
ISSN: 0014-4827
DOI: 10.1016/j.yexcr.2019.05.014
Rights: © 2019 Elsevier Inc. All rights reserved.
Fulltext Permission: none
Fulltext Availability: No Fulltext
Appears in Collections:SBS Journal Articles

SCOPUSTM   
Citations 20

9
Updated on Jan 28, 2023

Web of ScienceTM
Citations 20

8
Updated on Jan 26, 2023

Page view(s)

177
Updated on Jan 30, 2023

Google ScholarTM

Check

Altmetric


Plumx

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.